Form 6-K REGENTIS BIOMATERIALS For: Jul 15

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of July 2026

 

Commission file number: 001-42834

 

REGENTIS BIOMATERIALS LTD.

(Translation of registrant’s name into English)

 

60 Medinat Hayehudim Street, 4676652, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

 

 

CONTENTS

 

On July 15, 2026, Regentis Biomaterials Ltd. issued a press release entitled “Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch.” A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

Exhibit Index

 

Exhibit No.		Description
99.1		Press Release dated July 15, 2026.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Regentis Biomaterials Ltd.
Date: July 15, 2026	By:	/s/ Ori Gon
	Name:	Ori Gon
	Title:	Chief Financial Officer

 

 

 

2

 

ATTACHMENTS / EXHIBITS

PRESS RELEASE DATED JULY 15, 2026

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ANAC Publishes Proposed Noise Certification Criteria for Eve 100
• The Tax Refinery Announces Year Round Tax Advisory Model to Help Business Owners Shift From Reactive Filing to Strategic Planning
• Newport Beach Rehab Cites Client Reviews on Gender-Specific Care